Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
The Oncologist|December 8, 2009
A case of bullous dermatitis induced by erlotinibAlessandro Oteri, Maria Teresa Cattaneo, Virginio Filipazzi, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 25, 2021
The emotional impact of the COVID-19 outbreak on cancer outpatients and their caregivers: results of a survey conducted in the midst of the Italian pandemicMaria Silvia Cona, Eliana Rulli, Davide Dalu, et al.
Tumori|May 5, 2026
The impact of bio-psycho-social factors on mental health outcomes in patients with solid tumorsRaffaela D G Sartori, Davide Dalu, Davide De Francesco, et al.
The Pharmacogenomics Journal|March 2, 2021
Single nucleotide polymorphisms to predict taxanes toxicities and effectiveness in cancer patientsSara Demurtas, Nicla La Verde, Selene Rota, et al.
Tumori|October 25, 2014
Granulocyte colony-stimulating factors used in clinical practice: PoloNord Registry-Based Cohort Italian StudyDaniele Fagnani, Luciano Isa, Magda Franca Verga, et al.
Cancer Chemotherapy and Pharmacology|February 24, 2019
ABCB1 c.3435C>T polymorphism is associated with platinum toxicity: a preliminary studyBeatrice De Troia, Davide Dalu, Virginio Filipazzi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2007
Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studiesCesare Gridelli, Paolo Maione, Alfonso Illiano, et al.
Blood|July 5, 2003
Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT typeAnnarita Conconi, Giovanni Martinelli, Catherine Thiéblemont, et al.
Clinical Lung Cancer|January 15, 2014
Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancerCesare Gridelli, Antonio Rossi, Massimo Di Maio, et al.
Clinical Lung Cancer|June 28, 2020
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non-small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective StudyAndrea Luciani, Antonio Marra, Luca Toschi, et al.
Pageof 2